Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors

V. Gunmalm, N. R. Jørgensen, B. Abrahamsen, P. Schwarz*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

Breast cancer (BC) is the most common cancer amongst women worldwide. Bone health is emerging as an important issue for BC survivors. In this literature study, we focus on agents for preventing bone loss in early non-metastatic estrogen receptor positive BC in treatment with aromatase inhibitors (AI) and to assess the evidence for antiresorptive treatment of bone loss in early non-metastatic breast cancer. We included randomized controlled trials (RCT's) comparing: (a) bisphosphonates and control; (b) different bisphosphonates; (c) denosumab and control and (d) bisphosphonates vs. denosumab in early non-metastatic BC women in AI treatment. Among antiresorptives, zoledronic acid currently has the highest evidence for prevention of AI associated bone loss in early non-metastatic BC. Data on fracture prevention among all patients, elderly and old is sparse. More randomized controlled studies are needed with the focus of bone loss and fracture prevention especially among the elderly and old early non-metastatic BC women.

OriginalsprogEngelsk
Sider (fra-til)408-412
Antal sider5
TidsskriftEuropean Geriatric Medicine
Vol/bind8
Udgave nummer5-6
DOI
StatusUdgivet - nov. 2017

Fingeraftryk

Udforsk hvilke forskningsemner 'Evidence for the prevention of bone loss in elderly and old early non-metastatic breast cancer patients treated with aromatase inhibitors' indeholder.

Citationsformater